Schedules of Controlled Substances: Placement of Modafinil Into Schedule IV

FederalRegulations

Ask Donna

How this section applies to your facts.

Federal Register › Vol. 64 › 64 FR 4050

This text was captured on Sep 30, 2026. It is a snapshot, not a live feed, so check the official code before relying on it.

Text

DEPARTMENT OF JUSTICE

21 CFR Part 1308

[DEA-17F]

Schedules of Controlled Substances: Placement of Modafinil Into

Schedule IV

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Final rule.

-----------------------------------------------------------------------

SUMMARY: With the issuance of this final rule, the Deputy Administrator

of the Drug Enforcement Administration (DEA) places the substance,

modafinil, including its salts, isomers and salts of isomers, into

Schedule IV of the Controlled Substances Act (CSA). As a result of this

rule, the regulatory controls and criminal sanctions of Schedule IV

will be applicable to the manufacture, distribution, importation and

exportation of modafinil and products containing modafinil.

EFFECTIVE DATE: January 27, 1999.

FOR FURTHER INFORMATION CONTACT:

Frank Sapienza, Chief, Drug and Chemical Evaluation Section, Drug

Enforcement Administration,

Washington, DC 20537, Telephone: (202) 307-7183.

SUPPLEMENTARY INFORMATION: Modafinil is a central nervous system (CNS)

stimulant that produces many of the same pharmacological effects and

adverse reactions as classic psychomotor stimulants, but at higher

doses. Modafinil will be marketed as a prescription drug product for

the treatment of excessive daytime sleepiness associated with

narcolepsy under the trade name Provigil.

On December 22, 1997, the Acting Assistant Secretary for Health,

Department of Health and Human Services (DHHS), sent the Acting Deputy

Administrator of DEA a letter recommending that modafinil, and its

salts, be placed into Schedule IV of the CSA (21 U.S.C. 801 et seq.).

Enclosed with the December 22, 1997 letter was a document prepared by

the Food and Drug Administration (FDA) entitled ``Basis for the

Recommendation for Control of Modafinil in Schedule IV of the

Controlled Substances Act (CSA).'' The document contained a review of

the factors which the CSA requires the Secretary to consider (21 U.S.C.

811(b)).

Subsequent correspondent from the FDA's Associate Commissioner for

Health Affairs dated February 24, 1998, confirmed that the FDA had

determined that the New Drug Application (NDA) for modafinil was

``approvable'' and had issued an approvable letter to the NDA sponsor

on December 29, 1997. According to the February 24, 1998 letter from

the FDA, ``upon full approval of the NDA, modafinil will have a

currently accepted medical use in treatment in the United States.''

After a review of the available data, including the DHHS

recommendation, the Acting Deputy Administrator of the DEA, in an April

14, 1998 Federal Register notice (63 FR 18170), proposed placement of

modafinil into Schedule IV of the CSA, if and when the modafinil NDA is

approved by the FDA. The notice provided an opportunity for all

interested persons to submit their comments, objections, or requests

for hearing in writing to be received by the DEA on or before May 14,

1998.

The DEA received one comment regarding the proposal. The comment

was received from Cephalon, Inc., the company sponsoring the modafinil

NDA. The comment did not object to the placement of modafinil in

Schedule IV, but requested clarification of some of the descriptions of

the pharmacological effects of modafinil. Cephalon, Inc. commented that

modafinil did not produce significant dopaminergic activity nor did it

produce classic dopaminergic-like pharmacological effects. Cephalon

also stated that the time to peak pharmacological activity of modafinil

is one to three hours and the effects last six to eight hours after

oral administration. It did not characterize such pharmacodynamic

effects of modafinil as ``quick onset and short duration of action,''

as they were described in the Federal Register proposal.

The DEA's review of the DHHS scheduling recommendation and review

document and the available scientific literature indicates that the

precise biochemical mechanism of action of modafinil is not clearly

defined. Data indicate that modafinil does not act directly on any

single neurotransmitter system, but appears to act indirectly on

dopamineric, serotonergic, and GABA systems. Although its mechanism of

action may not be medicated primarily through the dopaminergic system,

the behavioral and pharmacological effects and adverse reactions

produced by modafinil are similar to those of other psychomotor or

stimulants which produce significant dopaminergic activity. The data

reviewed by the DHHS and the DEA show that modafinil is well-absorbed

after oral administration. Peak plasma concentration for modafinil

occurs at one to four hours. Elimination half-life was nine to fourteen

hours after oral administration of 200 to 400 mg of modafinil. These

pharmacodynamic actions of modafinil were characterized at ``fast onset

and short duration'' by the DHHS. Thus, the modafinil data presented in

the Federal Register proposal and the comments by Cephalon regarding

these statements are not substantive scientific discrepancies, but are

differences in describing the same data.

On December 30, 1998, the FDA notified the DEA that the modafinil

NDA was approved by the FDA on December 24, 1998. Relying on the

scientific and medical evaluation and the recommendation of the DHHS

Acting Assistant Secretary for Health received in accordance with

section 201(b) of the Act (21 U.S.C. 811(b)), communication with the

FDA Associate Commissioner for Health and the independent review of the

DEA, the Deputy Administrator of the DEA, pursuant to sections 201(a)

and 201(b) of the Act (21 U.S.C. 811(a) and 811(b)), finds that:

(1) Based on information now available, modafinil has a low

potential for abuse relative to the drugs or other substances in

Schedule III;

(2) Modafinil has a currently accepted medical use in treatment in

the United States; and

(3) Abuse of modafinil may lead to limited physical dependence and

psychological dependence relative to the drugs or other substances in

Schedule III.

Based on these findings, the Deputy Administrator of the DEA

concludes that modafinil, including its salts, isomers and salts of

isomers, warrants control in Schedule IV of the CSA. In order to make

modafinil pharmaceutical products available for medical use as soon as

possible, the Schedule IV controls of modafinil will be effective

January 27, 1999. In the event that the regulations impose special

hardships on the registrants, the DEA will entertain any justified

request for an extension of time to comply with the Schedule IV

regulations regarding modafinil. The applicable regulations are as

follows:

1. Registration. Any person who manufactures, distributes,

dispenses, imports or exports modafinil or who engages in research or

conducts instructional activities with modafinil, or who proposes to

engage in such activities, must be registered to conduct such

activities in accordance with Part 1301 of Title 21 of the Code of

Federal Regulations.

2. Security. Modafinil must be manufactured, distributed and stored

in accordance with Secs. 1301.71, 1301.72(b), (c), and (d), 1301.73,

1301.74, 1301.75 (b) and (c) and 1301.76 of Title 21 of the Code of

Federal Regulations.

3. Labeling and Packaging. All labels on commercial containers of,

and all labeling of, modafinil which is distributed shall comply with

the requirements of Secs. 1302.03-1302.07 of Title 21 of the Code of

Federal Regulations.

4. Inventory. Registrants possessing modafinil are required to take

inventories pursuant to Secs. 1304.03, 1304.04 and 1304.11 of Title 21

of the Code of Federal Regulations.

5. Records. All registrants must keep records pursuant to

Secs. 1304.03, 1304.04 and 1304.21-1304.23 of Title 21 of the Code of

Federal Regulations.

6. Prescriptions. All prescriptions for modafinil are to be issued

pursuant to Secs. 1306.03-1306.06 and 1306.21-1306.26 of Title 21 of

the Code of Federal Regulations.

7. Importation and Exportation. All importation and exportation of

modafinil shall be in compliance with Part 1312 of Title 21 of the

Federal Code of Regulations.

8. Criminal Liability. Any activity with modafinil not authorized

by, or in violation of, the CAS or the Controlled

Substances Import and Export Act shall be unlawful.

In accordance with the provisions of the CSA (21 U.S.C. 811(a)),

this action is a formal rulemaking on the record after opportunity for

a hearing. Such proceedings are conducted pursuant to the provisions of

5 U.S.C. 556 and 557 and, as such, are exempt from review by the Office

of Management and Budget pursuant to Executive Order (E.O.) 12866,

Section 3(d)(1).

The Deputy Administrator, in accordance with the Regulatory

Flexibility Act (5 U.S.C. 605(b)), has reviewed this final rule and, by

approving it, certifies that it will not have a significant economic

impact on a substantial number of small entities. Modafinil is a new

drug in the United States; recent approval of the product and its

labeling by the FDA will allow it to be marketed once it is placed into

Schedule IV of the CAS. This final rule will allow these entities to

have access to a new pharmaceutical product.

This rule will not result in the expenditure by State, local and

tribal governments, in the aggregate, or by the private sector, of

$100,000,000 or more in any one year, and it will not significantly or

uniquely affect small governments. Therefore, no actions were deemed

necessary under provisions of the Unfunded Mandates Reform Act of 1995.

This rule is not a major rule as defined by section 804 of the

Small Business Regulatory Enforcement Fairness Act of 1996. This rule

will not result in an annual effect on the economy of $100,000,000 or

more; a major increase in costs or prices; or significant adverse

effects on competition, employment, investment, productivity,

innovation, or on the ability of United States-based companies to

compete with foreign-based companies in domestic and export markets.

This rule will not have substantial direct effects on the States,

on the relationship between the national government and the States, or

on the distribution of power and responsibilities among the various

levels of government. Therefore, in accordance with E.O. 12612, it is

determined that this rule does not have sufficient federalism

implications to warrant the preparation of a Federalism Assessment.

List of Subjects in 21 CFR Part 1308

Administrative practice and procedure, Drug traffic control,

Narcotics, Prescription drugs.

Under the authority vested in the Attorney General by section

201(a) of the CSA (21 U.S.C. 811(a)), and delegated to the

Administrator of the DEA by the Department of Justice regulations (28

CFR 0.100) and redelegated to the Deputy Administrator pursuant to 28

CFR 0.104, the Deputy Administrator hereby amends 21 CFR part 1308 as

follows:

PART 1308--[AMENDED]

1. The authority citation for 21 CFR part 1308 continues to read as

follows:

Authority: 21 U.S.C. 811, 812, 871(b) unless otherwise noted.

2. Section 1308.14 is amended by redesignating the existing

paragraphs (e)(7) through (e)(11) as (e)(8) through (e)(12) and by

adding a new paragraph (e)(7) to read as follows: Sec. 1308.14 Schedule

IV.

* * * * *

(e) * * *

(7) Modafinil................................................ 1680

* * * *

*

Dated: January 20, 1999.

Donnie R. Marshall,

Deputy Administrator, Drug Enforcement Administration.

[FR Doc. 99-1791 Filed 1-26-99; 8:45 am]

BILLING CODE 4410-09-M

This is a copy of a public record, reproduced as it was published. It is not legal advice, and it may not be the version a court would rely on. Check the official source before you cite it.

A word about cookies

We need a few to keep you signed in and the library working. The rest help us see which pages people use and where they get stuck. They stay off unless you say yes.

Schedules of Controlled Substances: Placement of Modafinil Into Schedule IV · 64 FR 4050 | Frix